Trial Profile

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lifileucel (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
Indications Malignant melanoma
Focus Registrational; Therapeutic Use
Acronyms innovaTIL-01
Sponsors Iovance Biotherapeutics

Most Recent Events

23 Apr 2025 According to an Iovance Biotherapeutics media release, rapid oral presentation of data from this study will be presented at the 2025 ASCO Annual Meeting.
26 Nov 2024 Status changed from active, no longer recruiting to completed.
12 Sep 2024 This trial has been completed in Hungary.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com